These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
475 related articles for article (PubMed ID: 26238347)
1. Efficacy and safety of body weight-adapted oral cholecalciferol substitution in dialysis patients with vitamin D deficiency. Zitt E; Sprenger-Mähr H; Mündle M; Lhotta K BMC Nephrol; 2015 Aug; 16():128. PubMed ID: 26238347 [TBL] [Abstract][Full Text] [Related]
2. Cholecalciferol Additively Reduces Serum Parathyroid Hormone Levels in Severe Secondary Hyperparathyroidism Treated with Calcitriol and Cinacalcet among Hemodialysis Patients. Zheng CM; Wu CC; Hung CF; Liao MT; Shyu JF; Hsu YH; Lu CL; Wang YH; Zheng JQ; Chang TJ; Lin YF; Lu KC Nutrients; 2018 Feb; 10(2):. PubMed ID: 29439405 [TBL] [Abstract][Full Text] [Related]
3. Monthly cholecalciferol administration in haemodialysis patients: a simple and efficient strategy for vitamin D supplementation. Jean G; Souberbielle JC; Chazot C Nephrol Dial Transplant; 2009 Dec; 24(12):3799-805. PubMed ID: 19622574 [TBL] [Abstract][Full Text] [Related]
4. Low-dose cholecalciferol supplementation and dual vitamin D therapy in haemodialysis patients. Dusilová-Sulková S; Šafránek R; Vávrová J; Horáček J; Pavlíková L; Palička V Int Urol Nephrol; 2015 Jan; 47(1):169-76. PubMed ID: 25262147 [TBL] [Abstract][Full Text] [Related]
5. Cholecalciferol supplementation in hemodialysis patients: effects on mineral metabolism, inflammation, and cardiac dimension parameters. Matias PJ; Jorge C; Ferreira C; Borges M; Aires I; Amaral T; Gil C; Cortez J; Ferreira A Clin J Am Soc Nephrol; 2010 May; 5(5):905-11. PubMed ID: 20203163 [TBL] [Abstract][Full Text] [Related]
6. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis. Brandi L Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159 [TBL] [Abstract][Full Text] [Related]
8. Impact of cholecalciferol treatment on biomarkers of inflammation and myocardial structure in hemodialysis patients without hyperparathyroidism. Bucharles S; Barberato SH; Stinghen AEM; Gruber B; Piekala L; Dambiski AC; Custodio MR; Pecoits-Filho R J Ren Nutr; 2012 Mar; 22(2):284-291. PubMed ID: 21908203 [TBL] [Abstract][Full Text] [Related]
9. Biochemical parameters after cholecalciferol repletion in hemodialysis: results From the VitaDial randomized trial. Massart A; Debelle FD; Racapé J; Gervy C; Husson C; Dhaene M; Wissing KM; Nortier JL Am J Kidney Dis; 2014 Nov; 64(5):696-705. PubMed ID: 24856872 [TBL] [Abstract][Full Text] [Related]
10. Evidence for persistent vitamin D 1-alpha-hydroxylation in hemodialysis patients: evolution of serum 1,25-dihydroxycholecalciferol after 6 months of 25-hydroxycholecalciferol treatment. Jean G; Terrat JC; Vanel T; Hurot JM; Lorriaux C; Mayor B; Chazot C Nephron Clin Pract; 2008; 110(1):c58-65. PubMed ID: 18724068 [TBL] [Abstract][Full Text] [Related]
11. On-line haemodiafiltration improves response to calcifediol treatment. Pérez-García R; Albalate M; de Sequera P; Alcázar R; Puerta M; Ortega M; Corchete E Nefrologia; 2012 Jul; 32(4):459-66. PubMed ID: 22652556 [TBL] [Abstract][Full Text] [Related]
12. Chronic hemodialysis patients without marked elevation of intact parathyroid hormone are also good candidates for early intervention with cinacalcet. Nishida H; Masakane I; Kudo K; Ito M; Tanida H; Koshika M; Nishida W; Tomita Y Ther Apher Dial; 2013 Jun; 17(3):325-31. PubMed ID: 23735149 [TBL] [Abstract][Full Text] [Related]
13. Cholecalciferol supplementation increases FGF23 in peritoneal dialysis patients with hypovitaminosis D: a randomized clinical trial. Ramirez-Sandoval JC; Arvizu-Hernandez M; Cruz C; Vazquez-Cantu B; Rojas-Concha LJ; Tamez L; Reynerio F; Gomez FE; Correa-Rotter R J Nephrol; 2019 Aug; 32(4):645-659. PubMed ID: 30888584 [TBL] [Abstract][Full Text] [Related]
14. Cholecalciferol supplementation in chronic kidney disease: restoration of vitamin D status and impact on parathyroid hormone. Garcia-Lopes MG; Pillar R; Kamimura MA; Rocha LA; Canziani ME; Carvalho AB; Cuppari L Ann Nutr Metab; 2012; 61(1):74-82. PubMed ID: 22889840 [TBL] [Abstract][Full Text] [Related]
16. Heterogeneity in serum 25-hydroxy-vitamin D response to cholecalciferol in elderly women with secondary hyperparathyroidism and vitamin D deficiency. Giusti A; Barone A; Pioli G; Girasole G; Razzano M; Pizzonia M; Pedrazzoni M; Palummeri E; Bianchi G J Am Geriatr Soc; 2010 Aug; 58(8):1489-95. PubMed ID: 20646099 [TBL] [Abstract][Full Text] [Related]
17. Effect of depot oral cholecalciferol treatment on secondary hyperparathyroidism in stage 3 and stage 4 chronic kidney diseases patients. Dogan E; Erkoc R; Sayarlioglu H; Soyoral Y; Dulger H Ren Fail; 2008; 30(4):407-10. PubMed ID: 18569914 [TBL] [Abstract][Full Text] [Related]
18. Vitamin D insufficiency and treatment with oral vitamin D3 in children with chronic kidney disease. Kari JA; Eldesoky SM; Bagdadi OT Saudi Med J; 2012 Jul; 33(7):740-4. PubMed ID: 22821307 [TBL] [Abstract][Full Text] [Related]
19. A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in participants with CKD not receiving dialysis. Chonchol M; Locatelli F; Abboud HE; Charytan C; de Francisco AL; Jolly S; Kaplan M; Roger SD; Sarkar S; Albizem MB; Mix TC; Kubo Y; Block GA Am J Kidney Dis; 2009 Feb; 53(2):197-207. PubMed ID: 19110359 [TBL] [Abstract][Full Text] [Related]
20. The tolerability and biochemical effects of high-dose bolus vitamin D2 and D3 supplementation in patients with vitamin D insufficiency. Leventis P; Kiely PD Scand J Rheumatol; 2009; 38(2):149-53. PubMed ID: 18991184 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]